Camilla Petrycer-Hansen, PhD

Camilla is a principal in Novo Holdings, where she is responsible for company creation and early investments as well as investments focused on anti-infectives under the REPAIR Impact Fund. Prior to joining Novo Holdings, Camilla spent 10 years in business development across academia, start-ups and industry. Camilla currently serves on the board of directors of Centauri, Hoba Therapeutics, Precirix, and Limmatech and is an observer in Muna Therapeutics and Hemab.

Camilla has a PhD in Medicinal Chemistry and a Master of Pharmacy degree from Copenhagen University.